Lisdexamfetamine
- Generic Name
- Lisdexamfetamine
- Brand Names
- Vyvanse
- Drug Type
- Small Molecule
- Chemical Formula
- C15H25N3O
- CAS Number
- 608137-32-2
- Unique Ingredient Identifier
- H645GUL8KJ
- Background
Lisdexamfetamine is a prodrug of dextroamphetamine, a central nervous system stimulant known as d-amphetamine, covalently attached to the naturally occurring amino acid L-lysine. Lisdexamfetamine is the first chemically formulated prodrug stimulant and was first approved by the FDA in April 2008. It was also approved by Health Canada in February 2009. Lisde...
- Indication
Lisdexamfetamine is indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in adults and pediatric patients six years and older. It is also indicated to treat moderate to severe binge eating disorder (BED) in adults. It is approved for use in the US and Canada.
- Associated Conditions
- Attention Deficit Hyperactivity Disorder (ADHD), Moderate Binge Eating Disorder (BED), Severe Binge Eating Disorder (BED)
- Associated Therapies
- -
Lisdexamfetamine for Adults With Bulimia Nervosa
- First Posted Date
- 2018-01-12
- Last Posted Date
- 2020-11-27
- Lead Sponsor
- Aaron Keshen
- Target Recruit Count
- 23
- Registration Number
- NCT03397446
- Locations
- 🇨🇦
Nova Scotia Health Authority, Halifax, Nova Scotia, Canada
Evaluation of the Effect and Safety of Lisdexamfetamine in Children Aged 6-12 With ADHD and Autism
- Conditions
- Interventions
- First Posted Date
- 2017-11-09
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- JPM van Stralen Medicine Professional
- Target Recruit Count
- 48
- Registration Number
- NCT03337646
- Locations
- 🇨🇦
Center for Pediatric Excellence, Ottawa, Ontario, Canada
Experimental fMRI Study of Guanfacine and Lisdexamfetamine in ADHD Adolescents
- Conditions
- Interventions
- First Posted Date
- 2017-11-07
- Last Posted Date
- 2022-08-17
- Lead Sponsor
- King's College London
- Target Recruit Count
- 20
- Registration Number
- NCT03333668
- Locations
- 🇬🇧
Institute of Psychiatry, Psychology & Neuroscience; King's College London, London, United Kingdom
IMProving Executive Function Study
- Conditions
- Interventions
- First Posted Date
- 2017-06-14
- Last Posted Date
- 2023-11-18
- Lead Sponsor
- University of Pennsylvania
- Target Recruit Count
- 69
- Registration Number
- NCT03187353
- Locations
- 🇺🇸
3535 Market Street, Philadelphia, Pennsylvania, United States
Pharmacokinetics of Lisdexamfetamine (Vyvanse®) in Post-bariatric Surgery Patients
- First Posted Date
- 2017-03-03
- Last Posted Date
- 2018-08-23
- Lead Sponsor
- North Dakota State University
- Target Recruit Count
- 20
- Registration Number
- NCT03070509
- Locations
- 🇺🇸
Neuropsychiatric Research Institute, Fargo, North Dakota, United States
Treatment of Traumatic Brain Injury (TBI)-Related Attention Deficits in Children
- Conditions
- Interventions
- First Posted Date
- 2016-03-18
- Last Posted Date
- 2020-07-13
- Lead Sponsor
- Vanderbilt University
- Target Recruit Count
- 20
- Registration Number
- NCT02712996
- Locations
- 🇺🇸
Vanderbilt Medical Center, Nashville, Tennessee, United States
Treatments for Fathers With ADHD and Their At-Risk Children (Fathers Too)
- Conditions
- Interventions
- First Posted Date
- 2016-02-05
- Last Posted Date
- 2018-09-12
- Lead Sponsor
- Seattle Children's Hospital
- Target Recruit Count
- 19
- Registration Number
- NCT02675400
- Locations
- 🇺🇸
Seattle Children's, Seattle, Washington, United States
Lisdexamfetamine in Binge Eating Disorder (BED): fMRI Effects
- First Posted Date
- 2016-01-20
- Last Posted Date
- 2016-01-20
- Lead Sponsor
- Lindner Center of HOPE
- Target Recruit Count
- 40
- Registration Number
- NCT02659488
- Locations
- 🇺🇸
Lindner Center of HOPE, Mason, Ohio, United States
Shire SCT: Lisdexamfetamine Treatment for ADHD and SCT
- Conditions
- Interventions
- First Posted Date
- 2015-12-18
- Last Posted Date
- 2021-11-16
- Lead Sponsor
- NYU Langone Health
- Target Recruit Count
- 38
- Registration Number
- NCT02635035
- Locations
- 🇺🇸
New York University School of Medicine, New York, New York, United States
🇺🇸Mount Sinai School of Medicine, New York, New York, United States
A Comparison of PRC-063 and Lisdexamfetamine in the Driving Performance of Adults With ADHD
- Conditions
- Interventions
- First Posted Date
- 2015-09-21
- Last Posted Date
- 2017-01-19
- Lead Sponsor
- Rhodes Pharmaceuticals, L.P.
- Target Recruit Count
- 40
- Registration Number
- NCT02555150
- Locations
- 🇺🇸
University of Virginia, Charlottesville, Virginia, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.